Details of the Drug Reposition

General Information of This Drug (ID: DM6Q7U4)

Drug Name
Lenalidomide   DM6Q7U4
Synonyms
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
17 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urinary bladder neoplasm DIS7HACE N.A. Approved [1]
Testicular lymphoma DISC2M2N N.A. Approved [1]
Splenic marginal zone lymphoma DISCGTZY N.A. Approved [1]
Small intestine lymphoma DISDOS6S N.A. Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified DIS5OHQF N.A. Approved [1]
MALT lymphoma DIS1AVVE N.A. Approved [1]
Leukemia DISNAKFL N.A. Approved [1]
Hepatosplenic T-cell lymphoma DIS7KMY9 N.A. Approved [1]
Complex regional pain syndrome type 1 DISEUIQP N.A. Approved [1]
Adult T-cell leukemia/lymphoma DIS882XU N.A. Approved [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Approved [2]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [1]
Prolymphocytic leukaemia DISDPPHX 2A82.1 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Waldenstrom macroglobulinemia DIS9O23I 2A85.4 Approved [1]
Large granular lymphocytic leukemia DISHOPPI 2A90.1 Approved [1]
Pain DIS4RWOW MG30-MG3Z Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 Indications(s)
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 2 [3]
Renal cell carcinoma DISQZ2X8 2C90 Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colon cancer DISVC52G 2B90.Z Investigative [1]
------------------------------------------------------------------------------------

References

1 Lenalidomide FDA Label
2 Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE)
3 Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
4 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors